卵巢癌患者手术治疗前后血清CA125、CA19-9、CEA和SA检测的临床评价

Clinical Evaluation of Determination the Changes of Serum CA125,CA19-9,CEA and SA Levels in Patients with Ovarian Cancer

目的:探讨了卵巢癌患者手术治疗前后血清CA125、CA19-9、CEA和SA检测的变化及临床意义。方法:应用放射免疫分析和化学法对32例卵巢癌患者进行了手术治疗前后血清CA125、CA19-9、CEA和SA检测,并与35名正常人作比较。结果:卵巢癌患者在治疗前血清CA125、CA19-9、CEA和SA水平非常显著地高于正常人组(P<0.01)。手术治疗6个月后则与正常人组比较无显著性差异(P>0.05)。结论:检测卵巢癌患者血清CA125、CA19-9、CEA和SA水平的变化对了解病情、观察疗效和预后判断均有重要的临床价值。

Objective To evaluate the clinical significance of determination of changes of serum CA125,CA19-9,CEA and SA levels after operation in patients with ovarian cancer.Methods Serum CA125,CA19-9,CEA（with RIA）,serum SA（with chemistry） levels were determined in 32 patients with ovarian cancer both before and after operation as well as in 35 controls.Results Before operation the serum CA125,CA19-9,CEA and SA levels were significantly higher in the patients than those in controls（P0.01）,6 months after operation,the levels were not obviously different from those in controls（P0.05）.Conclusion Detecting the serum CA125,CA19-9,CEA and SA levels after operation might be of prognostic importance in patients with ovarian cancer.